Candriam Investors Group

Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics

Retrieved on: 
Thursday, January 19, 2023

Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023.

Key Points: 
  • Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023.
  • The Sesen Bio Board recommends that stockholders vote “FOR” each of the proposals listed on the WHITE proxy card enclosed with the definitive proxy statement / prospectus.
  • In addition to the definitive proxy statement / prospectus, Sesen Bio has also mailed a letter to the Company’s stockholders.
  • The Sesen Bio Board of Directors unanimously believes the pending merger with Carisma Therapeutics is the most value maximizing option available for Sesen Bio stockholders.

Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics

Retrieved on: 
Wednesday, January 4, 2023

Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders.

Key Points: 
  • Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders.
  • The Sesen Bio Board of Directors remains confident that the pending merger with Carisma represents the most value maximizing path forward.
  • The Sesen Bio Board of Directors continues to believe the pending merger will provide significant value to Sesen Bio stockholders given Carisma's clinical-stage proprietary CAR-M platform that could transform treatment for patients with cancer and other serious disorders.
  • Sesen Bio is open to dialogue with all of its stockholders, as evidenced by the recently amended merger agreement.

Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

Retrieved on: 
Thursday, December 29, 2022

The issuance of the special cash dividend and CVR remain contingent on the closing of the pending transaction.

Key Points: 
  • The issuance of the special cash dividend and CVR remain contingent on the closing of the pending transaction.
  • The $45 million increase to the expected special cash dividend delivers even more direct and immediate cash value.
  • During such discussions, Sesen Bio and Carisma offered to significantly increase the amount of the special cash dividend by $45 million to approximately $70 million.
  • Based on the comprehensive review process conducted with the Sesen Bio Board of Directors, the payment of a special cash dividend without a concurrent transaction would be unlikely.

Neovia Logistics Announces Successful Completion of Business Recapitalization

Retrieved on: 
Tuesday, November 1, 2022

Neovia Logistics, a global supplier of logistics services, today announced the successful completion of its comprehensive business recapitalization and significant deleveraging of the companys balance sheet.

Key Points: 
  • Neovia Logistics, a global supplier of logistics services, today announced the successful completion of its comprehensive business recapitalization and significant deleveraging of the companys balance sheet.
  • Upon completion of the transaction, the Investor Group assumed a controlling ownership stake in Neovia and will continue to support the companys long-term growth.
  • With the completion of our recapitalization, we are moving forward with a stronger financial foundation as we continue growing and deepening our customer relationships, said Neovia CEO Chris Synek.
  • Neovia will use the proceeds of the financing to further invest in key business initiatives to support long-term growth.

IndexIQ Adds to Fast-Growing ESG ETF Suite with Two New Funds

Retrieved on: 
Tuesday, October 25, 2022

Mid Cap Equity ETF ( IQSM ) is a passively managed ESG focused strategy, benchmarked to the IQ Candriam ESG U.S.

Key Points: 
  • Mid Cap Equity ETF ( IQSM ) is a passively managed ESG focused strategy, benchmarked to the IQ Candriam ESG U.S.
  • These new funds expand on IndexIQs ongoing partnerships and product team-ups with Candriam and MacKay Shields, respectively, including the IQ Candriam ESG U.S. Large Cap Equity ETF ( IQSU ), the IQ Candriam ESG International Equity ETF ( IQSI ), and IQ MacKay ESG Core Plus Bond ETF ( ESGB ).
  • IndexIQ also introduced its own thematic ESG suite of Dual Impact ETFs, which offer compelling exposures and a way for investors to give back through their investments.
  • For more information on the funds and on IndexIQs full suite of ETF offerings, please visit our website here .

 Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors

Retrieved on: 
Wednesday, September 28, 2022

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), today announced that they sent the below letter to the Companys Board of Directors.

Key Points: 
  • Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), today announced that they sent the below letter to the Companys Board of Directors.
  • Members of the Board of Directors,
    As youre aware, Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we") are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company).
  • Earlier this month, we were successful in garnering support from our fellow stockholders to compel Pasithea to hold a Special Meeting of Stockholders (the Special Meeting) at which stockholders will be able to remove the members of the Companys Board of Directors (the Board).
  • We urge you as directors with fiduciary responsibilities to concede to stockholders will and hold the Special Meeting without further delay.

Applied Data Finance Builds Out Management Team

Retrieved on: 
Monday, July 25, 2022

Applied Data Finance , LLC (ADF), a leading technology-enabled lender and asset manager, today announced that financial services executives Sumeet Wadhera and Jeff Andrews have joined the companys management team as Chief Capital Officer and Chief Growth Officer, respectively.

Key Points: 
  • Applied Data Finance , LLC (ADF), a leading technology-enabled lender and asset manager, today announced that financial services executives Sumeet Wadhera and Jeff Andrews have joined the companys management team as Chief Capital Officer and Chief Growth Officer, respectively.
  • Wadhera and Andrews report to ADF President Jimmy Cannon, who previously held executive roles at Capital One and JP Morgan Chase.
  • ADFs cutting-edge platform is positioned to meet the borrowing needs of millions of consumers across the credit spectrum, Cannon said.
  • Prior to ADF, Wadhera was a member of Australia and New Zealand Banking Groups (ANZ) institutional leadership team for the United States, Europe and Asia.

Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5

Retrieved on: 
Thursday, June 23, 2022

It is clear to us that the sitting directors are more focused on entrenchment than on advancing stockholders best interests.

Key Points: 
  • It is clear to us that the sitting directors are more focused on entrenchment than on advancing stockholders best interests.
  • We intend to investigate all aspects of this very troubling transaction, including for any breaches of fiduciary duty by the Board of Directors.
  • We also question why a transaction in which a Pasithea director had a financial interest was not presented to stockholders for approval.
  • Promptly after filing their definitive special meeting request statement with the SEC, the Participants intend to mail such statement and a WHITE special meeting request card to Pasithea stockholders.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends SpartanNash Shareholders Vote “FOR” SpartanNash’s Highly Qualified Director Nominees

Retrieved on: 
Tuesday, May 31, 2022

Food solutions company SpartanNash (the Company) (Nasdaq: SPTN) today announced that leading independent proxy advisory firm Glass Lewis & Co (Glass Lewis) has recommended that shareholders vote FOR all of SpartanNash director nominees on the WHITE proxy card at the Companys 2022 Annual Meeting of Shareholders scheduled for June 9, 2022.

Key Points: 
  • Food solutions company SpartanNash (the Company) (Nasdaq: SPTN) today announced that leading independent proxy advisory firm Glass Lewis & Co (Glass Lewis) has recommended that shareholders vote FOR all of SpartanNash director nominees on the WHITE proxy card at the Companys 2022 Annual Meeting of Shareholders scheduled for June 9, 2022.
  • Commenting on the Glass Lewis report, SpartanNash issued the following statement:
    We are pleased that Glass Lewis supports voting on the WHITE proxy card to elect all nine of the Companys highly qualified director nominees and clearly recognizes that SpartanNash has the right Board and the right strategy to continue to deliver enhanced value for shareholders.
  • The Company strongly urge shareholders to follow Glass Lewiss recommendation and vote FOR all of SpartanNashs nominees on the WHITE proxy card.
  • SpartanNash urges shareholders to elect each of SpartanNashs qualified and experienced director nominees by voting the WHITE proxy card today FOR: Douglas A. Hacker, M. Shn Atkins, Matthew Mannelly, Julien Mininberg, Jaymin Patel, Maj. Gen.

Macellum and Ancora Issue Supplemental Presentation Regarding SpartanNash

Retrieved on: 
Wednesday, May 18, 2022

We strongly believe that all three nominees, who collectively possess the right skills, experience and perspectives to help drive long-term value at SpartanNash.

Key Points: 
  • We strongly believe that all three nominees, who collectively possess the right skills, experience and perspectives to help drive long-term value at SpartanNash.
  • Macellum Capital Management is an activist investment firm, with deep expertise in the retail and consumer sectors, founded in 2009 by Jonathan Duskin.
  • Macellum prefers to constructively engage with management to improve its governance and performance for the benefit of all shareholders.
  • However, when management is entrenched, Macellum has run successful proxy contests to effectuate meaningful change.